查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
全球血液筛检市场 - 2023-2030
市场调查报告书
商品编码
1373367

全球血液筛检市场 - 2023-2030

Global Blood Screening Market - 2023-2030
出版日期: | 出版商: DataM Intelligence | 英文 185 Pages | 商品交期: 约2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

概述

进行血液筛检测试以识别感染迹象，以阻止受污染的血液和血液成分用于临床使用。进行血液筛检测试是为了检测没有任何疾病症状的人的潜在健康障碍或疾病。

血液筛检策略旨在确保血液单位的安全，但不应用于通知捐血者反应性检测结果。血液筛检测试中使用了多种技术，包括次世代定序、核酸检测和 ELISA。

市场动态

越来越多地进行血液筛检测试

对血液样本进行血液筛检测试，以提供有价值的资讯并诊断特定的医疗状况。血液筛检测试产品数量的增加是市场成长的重要动力。此外，许多重要公司透过推出新的血液筛检测试和试剂盒，在市场的进步中发挥重要作用。

例如，2023 年 10 月，Delfi Diagnostics 推出了基于血液的肺癌筛检测试。它的目的是提供一种更方便的检测方法，并且能够覆盖比目前标准更多的人。

此外，Quest Diagnostics 于2023 年8 月在美国推出了针对阿兹海默症的AD-Detect 检测，使其成为第一个可供消费者购买和评估阿兹海默症的潜在风险的血液生物标誌物检测。

此外，全球血液筛检市场受到捐血量增加等多种因素的推动，预计传染病发病率的增加将在预测期内推动市场。

血液筛检设备的严格监管审批和高成本

严格的监管要求可能会减缓新血液筛检技术或测试的批准和采用。此外，与血液筛检设备相关的高成本可能会阻碍市场成长。

目录

第 1 章：方法与范围

  • 研究方法论
  • 报告的研究目的和范围

第 2 章：定义与概述

第 3 章：执行摘要

  • 按产品类型分類的片段
  • 技术片段
  • 最终使用者的片段
  • 按地区分類的片段

第 4 章：市场动态

  • 影响因素
    • 司机
      • 越来越多地进行血液筛检测试
      • YY
    • 限制
      • 血液筛检设备的严格监管审批和高成本
      • YY
    • 机会
    • 影响分析

第 5 章：产业分析

  • 波特五力分析
  • 供应链分析
  • 定价分析
  • 监管分析
  • DMI 意见

第 6 章：COVID-19 分析

  • COVID-19 分析
    • 新冠疫情爆发前的情景
    • 新冠疫情期间的情景
    • 新冠疫情后的情景
  • COVID-19 期间的定价动态
  • 供需谱
  • 疫情期间政府与市场相关的倡议
  • 製造商策略倡议
  • 结论

第 7 章：按产品类型

  • 仪器
    • 直接购买
    • 租购
  • 试剂和试剂盒
    • NAT 试剂和试剂盒
      • 标准和控制
      • 标记和检测试剂
      • 酶和聚合酶
      • 探针和引子
      • 缓衝液、核苷酸和溶液
    • ELISA 试剂和试剂盒
      • 缀合物（抗原或抗体缀合成酶）
      • 免疫吸附剂
      • 控制
      • 基材
      • 样品稀释剂和清洗溶液
      • 其他试剂

第 8 章：按技术

  • 新一代定序 (NGS)
  • 新一代定序 (NGS)
    • 即时聚合酶炼式反应 (PCR)
    • 转录介导的扩增 (TMA)
  • 酵素连结免疫吸附测定法 (ELISA)
    • ELISA，依平台
      • 萤光免疫分析 (FIA)
      • 化学发光免疫分析 (CLIA)
      • 比色免疫分析 (CI)
    • ELISA，依世代
      • 第一代 ELISA
      • 第二代ELISA
      • 第三代ELISA
      • 第四代及以上
  • 蛋白质印迹分析
  • 快速测试
  • 其他的

第 9 章：最终用户

  • 医院
  • 血库
  • 其他的

第 10 章：按地区

  • 北美洲
    • 我们
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙
    • 欧洲其他地区
  • 南美洲
    • 巴西
    • 阿根廷
    • 南美洲其他地区
  • 亚太
    • 中国
    • 印度
    • 日本
    • 澳洲
    • 亚太其他地区
  • 中东和非洲

第 11 章：竞争格局

  • 竞争场景
  • 市场定位/份额分析
  • 併购分析

第 12 章：公司简介

  • Bio-Rad Laboratories, Inc.
    • 公司简介
    • 产品组合和描述
    • 财务概览
    • 主要进展
  • Grifols
  • Abbott Laboratories
  • F. Hoffmann-La Roche
  • Siemens Healthineers
  • Biomerieux
  • Thermo Fisher Scientific, Inc.
  • Ortho Clinical Diagnostics, Inc.
  • Becton, Dickinson, and Company
  • Beckman Coulter (Danaher Corporation)

第 13 章：附录

简介目录
Product Code: CD1618

Overview

Blood screening tests are performed to identify infection signs in order to stop the distribution of contaminated blood and blood components for clinical use. A blood screening test is done to detect potential health disorders or diseases in people who do not have any symptoms of the disease.

Blood screening strategies are designed to assure the safety of blood units, but should not be used for notifying blood donors of reactive test results. Various technologies are used in blood screening tests which include next-generation sequencing, nucleic acid tests, and ELISA.

Market Dynamics

Increasing launches of blood screening tests

Blood screening tests are performed on a blood sample to provide valuable information and diagnose specific medical conditions. The increasing number of product launches for blood screening tests acts as a significant driver for market growth. Also, many significant companies play a major role in the advancements of the market by launching new blood screening tests and kits.

For instance, in October 2023, Delfi Diagnostics launched a blood-based lung cancer screening test. It aims to provide a more convenient detection method and one that's capable of reaching a greater number of people than the current standard.

Additionally, in August 2023, Quest Diagnostics introduced its AD-Detect test for Alzheimer's disease in the United States by making it the first blood-based biomarker test available for consumers to purchase and assess the potential risks of developing Alzheimer's disease.

Furthermore, the global blood screening market is driven by various factors like rising blood donations, and an increase in the incidence of infectious diseases is expected to drive the market in the forecast period.

The stringent regulatory approvals and high cost of blood screening equipment

Stringent regulatory requirements can slow the approval and adoption of new blood screening technologies or tests. Also, the high cost associated with blood screening equipment can hamper the market growth.

Segment Analysis

The global blood screening market is segmented based on product type, technology, end users, and region.

Reagents and kits accounted for approximately 48.4% of the market share

The anti-A, anti-B, and anti-A, B reagents are used in the red blood cell determination of the ABO blood group. They are used to determine the absence or presence of erythrocytic antigens A or B on the surface of human red blood cells. Reagents and kits are expected to hold the largest market share over the period forecast owing to the high requirement for reagents, kits, and product launches.

For instance, in June 2023, Sysmex launched an assay kit to identify Amyloid Beta (AB) accumulation in the brain that causes Alzheimer's disease by using a small amount of blood.

Additionally, in July 2021, Ortho Clinical Diagnostics launched its VITROS Immunodiagnostic Products IL-6 Reagent Pack which is the latest addition to Ortho's VITROS Critical Care blood screening menu.

Geographical Analysis

North America is expected to hold a significant position in the global blood screening market share

The global blood screening market is segmented into North America, Europe, Asia Pacific, South America, Middle East, and Africa.

North America has maintained a significant market proportion due to factors such as the rising blood transfusion rates, and product launches, this trend is anticipated to continue throughout the forecast period.

For instance, according to the American Red Cross, in the United States, an estimated 10,000 units of plasma, roughly 7,000 units of platelets, and 36,000 units of red blood cells are needed per day. In the United States, more than 21 million blood components are transfused annually.

Additionally, in September 2023, Oxford BioDynamics, Plc. Launched its 94% accurate EpiSwitch prostate screening blood test for men with prostate cancer risk.

COVID-19 Impact Analysis:

The COVID-19 pandemic has had a significant impact on the global blood screening market. The onset of the pandemic in early 2020 led to widespread lockdowns and restrictions, impacting regular diagnoses, treatments, device launches, and consultations worldwide. With the outbreak of the pandemic, many pharmaceutical or medical device manufacturing units faced labor shortages and were unable to travel to work due to lockdown restrictions. Therefore, owing to the above factors, the blood screening market is expected to be moderately affected over the forecast period.

Competitive Landscape

The major global players in the market include: Bio-Rad Laboratories, Inc., Grifols S.A, Abbott Laboratories, F. Hoffmann-La Roche, Siemens Healthineers, Biomerieux, Thermo Fisher Scientific, Inc., Ortho Clinical Diagnostics, Inc., Becton, Dickinson, and Company, Beckman Coulter (Danaher Corporation). Among others.

Key Developments

  • In March 2023, H.U. Group Holdings Inc. introduced the Lumipulse G NfL CSF and Lumipulse G NfL Blood assays for the fully automated random-access LUMIPULSE G immunoassay systems. These CLEIA (chemiluminescent enzyme immunoassay) assays allow for the quantitative measurement of Neurofilament light (NfL) in human cerebrospinal fluid (CSF) and plasma.
  • In June 2021, Grail launched the Galleri blood screening test which is a multi-cancer screening capable of detecting many cancers.

Why Purchase the Report?

  • To visualize the global blood screening market segmentation based on product type, technology, end users and region as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of blood screening market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as excel consisting of key products of all the major players.

The global blood screening market report would provide approximately 61 tables, 58 figures, and 185 Pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Product Type
  • 3.2. Snippet by Technology
  • 3.3. Snippet by End User
  • 3.4. Snippet by Region

4. Market Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increasing launches of blood screening tests
      • 4.1.1.2.
    • 4.1.2. Restraints
      • 4.1.2.1. The stringent regulatory approvals and high cost of blood screening equipment
      • 4.1.2.2.
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Force Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis
  • 5.5. DMI Opinion

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Scenario Before COVID
    • 6.1.2. Scenario During COVID
    • 6.1.3. Scenario Post COVID
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Product Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 7.1.2. Market Attractiveness Index, By Product Type
  • 7.2. Instruments*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
    • 7.2.3. Outright Purchase
    • 7.2.4. Rental Purchase
  • 7.3. Reagents & Kits
    • 7.3.1. NAT Reagents & Kits
      • 7.3.1.1. Standards and Controls
      • 7.3.1.2. Labeling and Detection Reagents
      • 7.3.1.3. Enzymes and Polymerases
      • 7.3.1.4. Probes and Primers
      • 7.3.1.5. Buffers, Nucleotides, and Solutions
    • 7.3.2. ELISA Reagents & Kits
      • 7.3.2.1. conjugates (Antigen Or Antibody-Conjugated Enzyme)
      • 7.3.2.2. Immunosorbents
      • 7.3.2.3. Controls
      • 7.3.2.4. Substrates
      • 7.3.2.5. Sample Diluents and Wash Solutions
      • 7.3.2.6. Other Reagents

8. By Technology

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 8.1.2. Market Attractiveness Index, By Technology
  • 8.2. Next-Generation Sequencing (NGS) *
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Next-Generation Sequencing (NGS)
    • 8.3.1. Real-Time Polymerase Chain Reaction (PCR)
    • 8.3.2. Transcription-Mediated Amplification (TMA)
  • 8.4. Enzyme-Linked Immunosorbent Assay (ELISA)
    • 8.4.1. ELISA, By Platform
      • 8.4.1.1. Fluorescence Immunoassay (FIA)
      • 8.4.1.2. Chemiluminescence Immunoassay (CLIA)
      • 8.4.1.3. Colorimetric Immunoassay (CI)
    • 8.4.2. ELISA, By Generation
      • 8.4.2.1. First-Generation ELISA
      • 8.4.2.2. Second-Generation ELISA
      • 8.4.2.3. Third-Generation ELISA
      • 8.4.2.4. Fourth-Generation & Above
  • 8.5. Western Blot Assay
  • 8.6. Rapid Tests
  • 8.7. Others

9. By End Users

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End Users
    • 9.1.2. Market Attractiveness Index, By End Users
  • 9.2. Hospitals*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Blood Banks
  • 9.4. Others

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End Users
    • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End Users
    • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. UK
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Spain
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End Users
    • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia-Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End Users
    • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.5.7.1. China
      • 10.5.7.2. India
      • 10.5.7.3. Japan
      • 10.5.7.4. Australia
      • 10.5.7.5. Rest of Asia-Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End Users

11. Competitive Landscape

  • 11.1. Competitive Scenario
  • 11.2. Market Positioning/Share Analysis
  • 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

  • 12.1. Bio-Rad Laboratories, Inc.
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Financial Overview
    • 12.1.4. Key Developments
  • 12.2. Grifols
  • 12.3. Abbott Laboratories
  • 12.4. F. Hoffmann-La Roche
  • 12.5. Siemens Healthineers
  • 12.6. Biomerieux
  • 12.7. Thermo Fisher Scientific, Inc.
  • 12.8. Ortho Clinical Diagnostics, Inc.
  • 12.9. Becton, Dickinson, and Company
  • 12.10. Beckman Coulter (Danaher Corporation)

LIST NOT EXHAUSTIVE.

13. Appendix

  • 13.1. About Us and Services
  • 13.2. Contact Us